Urgent

Psoriasis (chronic plaque / guttate / generalised pustular / erythrodermic psoriasis)

psoriasis, plaque psoriasis, guttate, von Zumbusch, GPP, erythrodermic psoriasis, psoriasis vulgaris · Dermatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic immune-mediated (Th17/IL-23-IL-17 axis) scaling dermatosis. Most cases are stable plaque disease managed in the community, but generalised pustular psoriasis (GPP/von Zumbusch) and erythrodermic psoriasis are dermatological emergencies with fluid loss, sepsis risk and high-output failure. Guttate psoriasis classically follows streptococcal throat infection.

Red flags

  • Erythroderma (>90% BSA) with hypothermia/hyperthermia, tachycardia, hypotension - high-output failure/sepsis
  • Generalised pustular psoriasis with fever, leucocytosis, sheets of sterile pustules - von Zumbusch emergency
  • Pustular flare after oral steroid course or withdrawal
  • Signs of sepsis / secondary bacterial infection
  • Pregnancy with new pustular psoriasis (impetigo herpetiformis - maternal/fetal risk)
  • Acute arthritis / dactylitis suggesting psoriatic arthritis

Assessment

Differential diagnosis

  • Eczema / atopic dermatitis
  • Seborrhoeic dermatitis
  • Tinea corporis / incognito (KOH if unsure)
  • Cutaneous T-cell lymphoma / mycosis fungoides
  • Pityriasis rosea (guttate vs)
  • Drug eruption / AGEP (vs pustular psoriasis)
  • Erythroderma from drug reaction, eczema, CTCL
  • Secondary syphilis (guttate/palmoplantar)

Investigations

  • Clinical diagnosis; assess BSA and PASI-equivalent severity, nails, scalp, flexures, joints (screen for PsA)
  • If erythrodermic/pustular: FBC, U&E, CRP, LFTs, calcium, glucose, albumin, blood cultures if septic
  • Throat swab / ASOT if guttate (post-streptococcal)
  • Skin biopsy only if diagnosis unclear
  • Pre-biologic/systemic screen: FBC, LFTs, U&E, HIV, HBV/HCV, latent TB (IGRA/CXR), lipids, pregnancy test; HLA-C and IL36RN not routine
  • Temperature, fluid balance and sepsis screen in GPP

Management

  • Confirm phenotype; identify triggers (strep, drug withdrawal esp. oral steroids, lithium, beta-blockers, antimalarials, infection, alcohol)
  • Chronic plaque (limited): emollients + potent topical corticosteroid + vitamin D analogue; move to phototherapy (NB-UVB) or systemics if extensive/unresponsive
  • Guttate: treat streptococcal trigger; emollients + topical steroid/vit D; NB-UVB if widespread; usually self-limiting over weeks-months
  • Erythrodermic or generalised pustular psoriasis: ADMIT. Nurse warm, monitor temp/fluids/electrolytes, bland emollients, treat infection, VTE prophylaxis, avoid abrupt systemic steroid withdrawal (can precipitate GPP)
  • GPP acute flare: IL-36R inhibitor spesolimab is the preferred targeted therapy where available; alternatives ciclosporin, infliximab, or acitretin [verify local availability]
  • Do NOT give systemic corticosteroids to control chronic psoriasis - rebound/pustular flare on withdrawal
  • Refer to dermatology for systemic/biologic therapy; screen and treat psoriatic arthritis early

Drugs & doses

Emollients: liberal, e.g. 50:50 white soft paraffin/liquid paraffin, or emollient cream applied several times daily
Calcipotriol/betamethasone dipropionate gel or foam (e.g. Dovobet/Enstilar) once daily to body/scalp up to 4 weeks [verify local]
Potent topical corticosteroid, e.g. betamethasone valerate 0.1% ointment once-twice daily (avoid face/flexures); mometasone 0.1% od
Coal tar preparation or salicylic acid 2-5% for scale; dithranol for selected plaques [verify local]
Methotrexate 7.5-15 mg ORAL once WEEKLY (max ~25 mg/wk) with folic acid 5 mg weekly on a different day; monitor FBC/LFT; contraindicated in pregnancy [verify local dose]
Ciclosporin 2.5-5 mg/kg/day ORAL in 2 divided doses (short-term / crisis in erythrodermic & pustular disease; monitor BP, renal function) [verify local dose]
Acitretin 25-50 mg ORAL once daily (useful in pustular/erythrodermic; teratogen - avoid pregnancy and for 3 yrs after in women) [verify local dose]
Spesolimab 900 mg IV single infusion for GPP flare (second 900 mg IV at week 1 if persistent) [verify local availability/dose]
Biologics (specialist): adalimumab, secukinumab or ixekizumab (IL-17), guselkumab/risankizumab (IL-23), or infliximab; dose per product / weight [verify local]
Guttate: phenoxymethylpenicillin 500 mg ORAL four times daily 10 days if active streptococcal infection [verify local]

Disposition

Stable plaque/guttate: discharge with topical therapy and GP/dermatology follow-up. Erythrodermic or generalised pustular psoriasis: ADMIT (consider HDU) under dermatology with fluid/electrolyte support. Urgent dermatology referral for any systemic/biologic candidate or diagnostic doubt.

Complications & pitfalls

  • Secondary infection / bacteraemia
  • Dehydration, electrolyte and protein loss, hypothermia (erythroderma)
  • High-output cardiac failure
  • Psoriatic arthritis and irreversible joint damage
  • Metabolic syndrome, cardiovascular disease, NAFLD
  • Depression and significant quality-of-life impairment
  • Drug toxicity from systemic agents

Exam pearls

  • AAD 2024 and NICE CKS: topical corticosteroid + vitamin D analogue is first-line for plaque disease; step up to phototherapy then systemics/biologics (IL-17/IL-23) by severity
  • NEVER use systemic corticosteroids to clear chronic psoriasis - rebound and risk of GPP
  • Spesolimab (anti-IL-36R) is NICE-recommended for acute GPP flares; think IL-36 pathway in pustular disease
  • Guttate psoriasis: look for and treat streptococcal trigger; majority resolve
  • Auspitz sign (pinpoint bleeding on scale removal) and Koebner phenomenon support diagnosis
  • Always screen for psoriatic arthritis (PEST/early referral) - undertreated and erosive

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.